CAS 1058156-90-3: Anlotinib

Description: Anlotinib is a small molecule tyrosine kinase inhibitor primarily used in the treatment of various cancers, including non-small cell lung cancer and soft tissue sarcoma. Its chemical structure allows it to inhibit multiple receptor tyrosine kinases, which play a crucial role in tumor growth and angiogenesis. Anlotinib is characterized by its ability to interfere with signaling pathways that promote cancer cell proliferation and survival. The substance is typically administered orally and has shown efficacy in clinical trials, leading to its approval in certain regions for specific cancer types. Its pharmacokinetics indicate a moderate half-life, allowing for once-daily dosing, and it is metabolized primarily in the liver. Common side effects may include hypertension, fatigue, and gastrointestinal disturbances. As with many targeted therapies, monitoring for adverse effects and drug interactions is essential during treatment. Overall, Anlotinib represents a significant advancement in targeted cancer therapy, providing a therapeutic option for patients with limited treatment alternatives.

N/A

CAS: 1058156-90-31360460-82-7

• Formula: C₂₃H₂₂FN₃O₃HCl
• Molecular weight: 407.45 2* 36.46

N/A

CAS: 1058156-90-3

• Formula: C₂₃H₂₂FN₃O₃
• Molecular weight: 407.44

Anlotinib

CAS: 1058156-90-3

Anlotinib is a drug that belongs to the class of small-molecule tyrosine kinase inhibitors and …

• Formula: C₂₃H₂₂FN₃O₃
• Purity: Min. 95%
• Molecular weight: 407.45 g/mol